Application8505C cell line has been used to study the impact of synthetic manipulation of expression of microRNAs miR-25 and miR-222 in benign and malignant thyroid cells. It has also been used to determine the induction of pluripotency markers by mitogen activated protein kinase (MEK) inhibition.
Biochem/physiol ActionsEstablished from undifferentiated thyroid carcinomas of a 78 year old female patient. Pathologically this primary carcinoma tissue contained residual well differentiated components suggesting well differentiated to undifferentiated carcinoma progression. Tumour suppresser genes p53, Rb, APC and MCC were analysed and sequence analysis confirmed a C:G to G:C transversion at the first base of p53 gene codon 248. Polymerase chain reaction-loss of heterozygosity assays confirmed allelic deletion of p53 gene. Loss of heterozygosity of tumour suppresser genes was not observed.
Human thyroid carcinoma, undifferentiated.
Preparation NoteEMEM (HBSS) + 2mM Glutamine + 1% Non Essential Amino Acids (NEAA) + 10% Foetal Bovine Serum (FBS).
Split sub-confluent cultures (70-80%) 1:3 to 1:6 i.e. seeding at 2-4 x 10,000 cells/cm² using 0.25% trypsin/EDTA; 5% CO₂; 37°C. Doubling time is 36 hours. Saturation density at confluency is 1x100,000 cells/cm².
Other NotesAdditional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.
This cell line is part of the European Collection of Authenticated Cell Cultures (ECACC), an international repository managed by the United Kingdom Health Security Agency (UKHSA). No licensing agreement is required when either this cell line or the DNA extracted from it are used for internal research purposes only. Any other use of these products is prohibited without the express written permission of UKHSA. Inquiries regarding authorized use of this cell line or its genomic DNA may be directed to
[email protected].
